HOW MOTS-C PEPTIDE REGULATES GLUCOSE Clinical studies have shown that MOTS-c promotes the production of endogen AMP analogue AICAR, which in turn, helps in the synthesis of AMP-activated protein kinase [1] (also referred to as AMPK)
Important safety considerations include the risk of acute pancreatitis (seek urgent medical attention for severe, persistent abdominal pain), gallbladder disease, and potential worsening of diabetic retinopathy, particularly in patients with pre-existing retinopathy who experience rapid improvement in blood glucose control
Similar concerns apply to phosphodiesterase-5 inhibitors (medications like sildenafil) and L-arginine supplements that also influence nitric oxide signaling
Clinical Evidence for GLP-1 Receptor Agonists in Weight Management The STEP trials (Semaglutide Treatment Effect in People with Obesity) demonstrated that patients on semaglutide lost an average of 15.3% of body weight over 68 weeks, compared to 2.7% in the placebo group
Yes Published source: BMJ